Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Sep;97(9):e70597.
doi: 10.1002/jmv.70597.

Insights Into Kaposi Sarcoma-Associated Herpesvirus-Specific Humoral Responses

Dicle Yalcin  1 , Eric D Eymard  1   2 , Khushi Kiran  1   2 , Wema Kibanga  1   2   3 , Zhou Liu  1 , Charles Wood  1   2 , For Yue Tso  1   2
Affiliations
Review

Insights Into Kaposi Sarcoma-Associated Herpesvirus-Specific Humoral Responses

Dicle Yalcin et al. J Med Virol. 2025 Sep.

Abstract

Kaposi sarcoma (KS) remains a global health concern. In sub-Saharan Africa, where there is a high burden of HIV-1 infection, there is also a high prevalence of infection by the etiologic agent of KS, the KS-associated herpesvirus (KSHV). Despite the successes of antiretroviral treatment (ART), the burden of KS and other KSHV-associated malignancies among people living with HIV under ART remained high, stressing the need for a greater understanding of the immune response against KSHV infection. Here, we review the current information on KSHV-specific humoral response in infected individuals in detail. We discuss the significance of anti-KSHV responses, mechanisms used by KSHV to subvert and modulate humoral immunity, and implications for pathogenesis and therapy. We highlight cutting-edge serological assays and bioinformatics tools that aid the development of effective vaccines against KSHV, underscoring the complexity of the humoral response and its critical role within the context of infection and vaccine design.

Keywords: KSHV; humoral immunity; immunoinformatics; serology; vaccine development.

PubMed Disclaimer

References

    1. G. Sternbach and J. Varon, “Moritz Kaposi: Idiopathic Pigmented Sarcoma of the Skin,” Journal of Emergency Medicine 13, no. 5 (1995): 671–674.
    1. E. Cesarman, B. Damania, S. E. Krown, J. Martin, M. Bower, and D. Whitby, “Kaposi Sarcoma,” Nature Reviews Disease Primers 5, no. 1 (2019): 9.
    1. Y. Chang, E. Cesarman, M. S. Pessin, et al., “Identification of Herpesvirus‐Like DNA Sequences in AIDS‐associated Kaposi's Sarcoma,” Science 266, no. 5192 (1994): 1865–1869.
    1. E. Cesarman, Y. Chang, P. S. Moore, J. W. Said, and D. M. Knowles, “Kaposi's Sarcoma‐Associated Herpesvirus‐Like DNA Sequences in AIDS‐Related Body‐Cavity‐Based Lymphomas,” New England Journal of Medicine 332, no. 18 (1995): 1186–1191.
    1. M. Hayashi, K. Aoshiba, M. Shimada, Y. Izawa, S. Yasui, and A. Nagai, “Kaposi's Sarcoma‐Associated Herpesvirus Infection in the Lung in Multicentric Castleman's Disease,” Internal Medicine 38, no. 3 (1999): 279–282.

MeSH terms

Substances

LinkOut - more resources